live
world
emerg
new
diseas
old
diseas
resurg
aggress
form
drug
develop
pharmaceut
compani
marketdriven
costli
endeavor
thu
often
challeng
drug
need
diseas
endem
certain
region
affect
patient
howev
biomed
open
data
access
reusabl
reanalysi
gener
new
hypothes
discoveri
studi
leverag
biomed
data
tool
analyz
avail
data
nipah
viru
niv
infect
niv
infect
emerg
zoonosi
transmiss
human
associ
high
mortal
rate
studi
explor
applic
comput
drug
reposit
chemogenom
enrich
analys
use
host
transcriptom
data
match
drug
could
revers
virusinduc
gene
signatur
perform
analys
use
two
gene
signatur
previous
publish
gene
signatur
ii
gene
signatur
gener
use
characterist
direct
method
n
predict
framework
suggest
sever
drug
includ
fda
approv
therapi
like
beclometason
trihexyphenidyl
spropranolol
etc
could
modul
niv
infect
induc
gene
signatur
endotheli
cell
target
specif
analysi
also
suggest
potenti
applic
eldelumab
investig
therapi
crohn
diseas
ulcer
coliti
put
candid
drug
reposit
conclud
also
discuss
challeng
opportun
clinic
trial
adapt
trial
reposit
drug
followup
studi
includ
biochem
assay
clinic
trial
requir
identifi
effect
therapi
clinic
use
proofofconcept
studi
highlight
translat
bioinformat
method
includ
gene
express
analys
comput
drug
reposit
could
augment
epidemiolog
investig
context
emerg
diseas
effect
treatment
right
reserv
reus
allow
without
permiss
live
world
emerg
new
diseas
old
diseas
resurg
aggress
form
drug
develop
pharmaceut
compani
marketdriven
costli
endeavor
thu
often
challeng
drug
need
diseas
endem
certain
region
affect
patient
howev
biomed
open
data
access
reusabl
reanalysi
gener
new
hypothes
discoveri
studi
leverag
biomed
data
tool
analyz
avail
data
nipah
viru
niv
infect
niv
infect
emerg
zoonosi
transmiss
human
associ
high
mortal
rate
studi
explor
applic
comput
drug
reposit
chemogenom
enrich
analys
use
host
transcriptom
data
match
drug
could
revers
virusinduc
gene
signatur
perform
analys
use
two
gene
signatur
previous
publish
gene
signatur
ii
gene
signatur
gener
use
characterist
direct
method
n
predict
framework
suggest
sever
drug
includ
fda
approv
therapi
like
beclometason
trihexyphenidyl
spropranolol
etc
could
modul
niv
infect
induc
gene
signatur
endotheli
cell
target
specif
analysi
also
suggest
potenti
applic
eldelumab
investig
therapi
crohn
diseas
ulcer
coliti
put
candid
drug
reposit
conclud
also
discuss
challeng
opportun
clinic
trial
adapt
trial
reposit
drug
followup
studi
includ
biochem
assay
clinic
trial
requir
identifi
effect
therapi
clinic
use
proofofconcept
studi
highlight
translat
bioinformat
method
includ
gene
express
analys
comput
drug
reposit
could
augment
epidemiolog
investig
context
emerg
diseas
effect
treatment
nipah
viru
niv
member
paramyxovirida
famili
envelop
negativesens
singlestrand
rna
virus
niv
member
henipaviru
genu
henipavirus
includ
cedar
henipaviru
ghanaian
bat
henipaviru
hendra
henipaviru
mojiang
henipaviru
niv
infect
consid
emerg
infecti
diseas
threat
world
health
organ
see
http
wwwwhointcsrdiseasenipahen
niv
infect
first
report
viru
isol
outbreak
malaysia
singapor
late
niv
infect
reemerg
kozhikod
coastal
citi
kerala
india
kerala
reemerg
associ
high
mortal
rate
identifi
case
person
commun
see
http
present
approv
therapi
vaccin
niv
studi
explor
applic
translat
bioinformat
databas
tool
method
like
comput
drug
reposit
predict
potenti
fdaapprov
therapi
use
publicli
avail
dataset
followup
studi
includ
experiment
assay
clinic
trial
requir
use
reposit
candid
drug
clinic
use
niv
infect
character
combin
neurolog
respiratori
cardiovascular
complic
includ
limit
high
fever
seizur
enceph
mening
tremor
ptosi
dysarthria
dysphasia
respiratori
tract
lesion
sever
acut
respiratori
distress
syndrom
ard
tachycardia
myocard
vomit
hypertens
segment
myoclonu
along
without
clinic
featur
notabl
vaccin
candid
like
human
monoclon
antibodi
found
effect
preclin
studi
preclin
immunotherapi
studi
demonstr
monoclon
antibodi
might
benefici
antig
antif
mab
agent
niv
infect
small
molecul
activ
modul
rigilik
receptor
pathway
also
investig
potenti
strategi
target
niv
infect
drug
like
ribavirin
broad
spectrum
antivir
effect
rna
dna
virus
shown
associ
lower
mortal
rate
lack
conclus
evid
random
control
clinic
trial
evid
recent
studi
suggest
favipiravir
investig
treatment
influenza
may
prevent
niv
infect
hamster
model
effort
also
underway
develop
nucleic
acid
therapeut
niv
infect
therapi
need
full
cycl
clinic
trial
addit
evid
includ
compar
effect
understand
optim
contribut
outcom
drug
reposit
drug
repurpos
see
figur
drug
develop
strategi
design
reduc
time
develop
market
drug
diseas
approv
drug
diseas
may
need
better
therapi
rare
orphan
endem
neglect
diseas
may
ideal
area
research
develop
pharmaceut
compani
howev
drug
reposit
offer
altern
path
set
exampl
nation
institut
health
nation
center
advanc
translat
scienc
recommend
rare
neglect
diseas
current
lack
effect
treatment
could
benefit
drug
reposit
compar
tradit
drug
discoveri
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
authorfund
absenc
effect
antivir
agent
prophylact
vaccin
niv
human
imper
develop
better
therapeut
agent
address
infecti
diseas
threat
howev
pharmaceut
compani
limit
commerci
prospect
develop
drug
rare
orphan
neglect
infecti
diseas
endem
diseas
figur
datadriven
method
combin
comput
experiment
approach
could
complement
improv
reduc
cost
drug
discoveri
exampl
first
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
authorfund
bioinformat
develop
storag
analyt
interpret
method
optim
transform
increasingli
volumin
biomed
data
genom
data
proactiv
predict
prevent
participatori
health
studi
show
applic
translat
bioinformat
approach
comput
drug
reposit
find
potenti
therapi
target
niv
use
publicli
avail
dataset
tool
therapeut
option
target
epidemiolog
threat
limit
drug
reposit
viabl
therapeut
identif
strategi
howev
sinc
late
biomed
research
gener
deposit
varieti
biomolecular
data
relat
niv
publicli
access
biomolecular
databas
figur
illustr
methodolog
workflow
use
present
studi
method
includ
follow
compon
aggreg
niv
infect
gene
signatur
data
drug
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
authorfund
http
doi
biorxiv
preprint
reposit
comput
drug
reposit
use
niv
gene
signatur
follow
filter
interpret
critic
requir
comput
drug
reposit
avail
gene
express
dataset
relat
diseas
interest
queri
gene
express
leverag
cgea
method
first
use
signatur
induc
niv
endotheli
cell
line
form
upregul
downregul
gene
identifi
input
queri
gene
list
match
compound
connect
gene
signatur
compound
score
variou
filter
step
avail
druginduc
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
authorfund
portalsbroadinstituteorgccl
use
identifi
compound
concordantli
modul
queri
signatur
direct
toward
away
input
queri
gaussian
mixtur
model
use
deriv
connect
score
statist
signific
estim
use
kolmogorovsmirnov
test
benjaminihochberg
method
control
fals
discoveri
rate
cgea
produc
output
rank
list
candid
compound
may
potenti
modul
biolog
state
interest
depend
queri
signatur
refer
databas
mani
candid
compound
often
extract
list
trim
priorit
like
candid
use
annot
refer
databas
exampl
repurposedb
kegg
drug
drugbank
etc
also
use
specif
characterist
includ
mechan
action
side
effect
chemic
properti
biolog
target
seven
antivir
agent
avail
dataset
follow
effect
least
effect
order
publish
gene
signatur
ribavirin
vidarabin
moroxydin
zidovudin
saquinavir
zalcitabin
ganciclovir
sever
score
indic
activ
signific
fdr
correct
ribavirin
lowest
score
indic
potent
activ
follow
order
activ
characterist
direct
base
gene
signatur
saquinavir
ganciclovir
moroxydin
vidarabin
zalcitabin
zidovudin
ribavirin
ribavirin
least
effect
exampl
gene
number
gene
signatur
direction
gene
could
influenc
rank
compound
also
note
moroxydin
optim
direct
score
gene
set
statist
signific
moroxydin
antivir
agent
structur
similar
ribavirin
conserv
structur
moieti
often
indic
similar
chemic
activ
addit
studi
requir
elucid
role
moroxydin
antiniv
agent
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
authorfund
http
doi
biorxiv
preprint
cxc
motif
chemokin
synonym
antimicrobi
gene
encod
chemokin
cxc
subfamili
ligand
receptor
gene
express
across
signatur
figur
figur
b
precis
medicin
aim
leverag
molecular
profil
data
recommend
medic
base
individu
patient
risk
profil
exist
medic
comorbid
nonclin
factor
like
diet
environment
exposur
precis
medicin
approach
leverag
mutat
profil
recommend
therapi
emerg
standard
care
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
authorfund
sever
clinic
trial
design
method
report
medic
literatur
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
authorfund
http
doi
biorxiv
preprint
trial
involv
measur
singl
patient
repeatedli
time
introduc
differ
therapi
could
multipl
activ
therapi
compar
therapi
placebo
addit
individuallevel
analys
understand
therapeut
effect
particular
patient
sever
trial
statist
aggreg
outcom
also
explor
furthermor
strongest
form
trial
requir
baselin
phase
without
treatment
treatment
phase
introduc
drug
also
requir
treatment
withdraw
washout
period
observ
effect
reintroduc
treatment
posit
effect
drug
observ
withdraw
may
possibl
ethic
ground
washout
period
without
treatment
may
also
harm
patient
safeti
given
scenario
form
singlesubject
design
requir
treatment
withdraw
multipl
baselin
design
baselin
phase
altern
treatment
design
could
consid
improv
confid
result
trial
design
random
could
incorpor
summar
endors
one
method
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
authorfund
http
doi
biorxiv
preprint
discuss
variou
option
clinic
trial
design
follow
person
medicin
approach
explor
infecti
diseas
multipl
therapeut
option
context
drug
reposit
candid
research
studi
sever
limit
data
base
infect
induc
huvec
cell
huvec
cell
may
reflect
differenti
gene
express
affect
tissu
diseas
interest
absenc
patient
deriv
genom
transcriptom
data
set
drug
list
less
reliabl
human
test
without
addit
experiment
evid
low
sampl
size
gene
signatur
may
fluctuat
higher
lower
number
gene
base
sampl
size
statist
test
multipl
test
correct
method
sampl
size
meet
biolog
replic
criteria
minimum
three
sampl
drug
reposit
algorithm
predict
natur
endors
immedi
clinic
use
without
preclin
clinic
studi
offlabel
prescript
recommend
would
need
addit
compar
effect
trial
drug
also
research
studi
list
drug
compil
result
section
need
evalu
preclin
valid
model
need
test
patient
cohort
use
differ
clinic
trial
modal
includ
compar
effect
trial
variou
factor
drive
success
statist
valid
predict
framework
includ
avail
qualiti
data
choic
analyt
algorithm
orthogon
evid
statist
method
account
larg
number
data
point
restrict
result
interpret
discuss
drug
drugbank
howev
compound
may
superior
antiniv
activ
compound
would
need
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
authorfund
http
doi
biorxiv
preprint
extens
multiyear
trial
toxic
profil
clinic
test
use
clinic
set
base
predict
evid
drug
reposit
could
drug
identif
strategi
absenc
readi
prescrib
fdaapprov
therapi
context
emerg
viru
high
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
authorfund
http
doi
biorxiv
preprint
mortal
rate
short
turnaround
time
proof
concept
studi
explor
applic
comput
drug
reposit
chemogenom
enrich
analys
use
hostviru
transcriptom
data
specif
perform
comput
drug
match
search
find
drug
revers
viru
induc
gene
signatur
endotheli
cell
line
set
niv
infect
briefli
translat
bioinformat
approach
epidemiolog
effort
may
help
acceler
discoveri
afford
therapeut
option
public
health
crise
includ
emerg
infecti
diseas
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
authorfund
http
doi
biorxiv
preprint
copyright
holder
preprint
peerreview
authorfund
http
doi
biorxiv
preprint
e
u
r
e
l
e
v
e
l
f
r
h
u
n
f
p
r
e
e
r
c
r
h
e
l
h
n
e
e
b
p
r
e
e
r
l
n
c
p
